Professor (Hon.) Mark Sullivan

Skills and experience

Mark Sullivan is a clinical and regulatory scientist with comprehensive experience of the development of new medicines for infectious diseases. He is the founder and CEO/Managing Director of Medicines Development for Global Health (MDGH), the world’s only non-profit biopharmaceutical company and the first to achieve FDA approval of a novel medicine: moxidectin. His career highlights include 17 years executive management and Board of Directors experience in biotechnology and over 30 years’ experience in product development having formerly worked at GSK (London) and Gilead Sciences, Inc. (California). He has led global cross functional project teams, regulatory interactions (including peri- and post-application) and has personally run and/or had responsibility for over 100 clinical trials at all stages of development. Formerly, he was Chief Operating Officer of Australia’s HIV vaccine design and development consortium and a HIV prevention microbicide program, both NIH funded.

Education

Mark is an honorary Professor from the University of New South Wales and was made an Officer of the Order of Australia in 2022. Mark received his Bachelor of Science in Biochemistry from Deakin University.